Vanguard Group
MPLT

Vanguard Group’s MapLight Therapeutics MPLT Stock Holding History

Vanguard Group’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$15.3M Buy
+869,668
New +$14.6M ﹤0.01% 2750

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group's MPLT Position: Q4 2025 in Review

Vanguard Group opened a new position in MapLight Therapeutics (MPLT) in Q4 2025: 869,668 shares worth $15.3M. The stake represents ﹤0.01% of the portfolio and ranks #2750 among its holdings.

74 funds tracked by Wall St. Rank hold MPLT as of Q4 2025.

  • Vanguard Group held 869,668 shares of MapLight Therapeutics worth $15.3M as of Q4 2025.
  • MapLight Therapeutics was a new Vanguard Group position in Q4 2025.
  • MapLight Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2750 holding.
  • 74 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.